pLenti4/TO-hEPO
(Plasmid
#50437)
-
Purposeexpress human erythropoietin under the control of tetracycline-regulatable CMV promoter using lentiviral delivery system
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 50437 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLenti4/TO/V5-DEST gateway vector
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 8598
- Total vector size (bp) 9200
-
Vector typeMammalian Expression, Lentiviral ; Tetracycline-regulatable (T-REx)
-
Selectable markersZeocin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameEPO
-
Alt nameerythropoietin
-
Alt nameMVCD2
-
SpeciesH. sapiens (human)
-
Insert Size (bp)582
-
Entrez GeneEPO (a.k.a. DBAL, ECYT5, EP, MVCD2)
- Promoter CMV/TO
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer CMV-F (Common Sequencing Primers)
Resource Information
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Human erythropoietin (hEPO) ORF with stop codon (582 bp; Ultimate ORF clone number IOH7334) from GeneCopoeia ORF cDNA clones in pDONR vector (GeneCopoeia; GC-A1011)
Because the stop codon is inserted before V5 epitope, the V5 tag on the pLenti6.3/V5-DEST vector won’t be transcribed.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLenti4/TO-hEPO was a gift from Juan Melero-Martin (Addgene plasmid # 50437 ; http://n2t.net/addgene:50437 ; RRID:Addgene_50437) -
For your References section:
Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release. Lin RZ, Dreyzin A, Aamodt K, Li D, Jaminet SC, Dudley AC, Melero-Martin JM. Blood. 2011 Nov 17;118(20):5420-8. doi: 10.1182/blood-2011-08-372946. Epub 2011 Sep 21. 10.1182/blood-2011-08-372946 PubMed 21937702